Stay updated on T-VEC + Pembrolizumab in Sarcoma Clinical Trial

Sign up to get notified when there's something new on the T-VEC + Pembrolizumab in Sarcoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the T-VEC + Pembrolizumab in Sarcoma Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The sarcoma trial record is displayed, including its recruitment status, eligibility criteria, treatment plan, locations, outcome measures, and study documents.
    Difference
    50%
    Check dated 2026-11-11T02:03:08.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The footer’s site revision label changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-04T00:46:00.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    A site-wide NIH notice about its website transition and terminology appears above the page, and the site revision changes from v3.7.1 to v3.7.2. The study page itself continues to display a 403 error.
    Difference
    1%
    Check dated 2026-10-21T00:45:31.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changes from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-07T00:53:56.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study content with an error screen. As a result, users cannot view the study overview, eligibility criteria, locations, or contacts.
    Difference
    18%
    Check dated 2026-09-23T01:11:10.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    The page's revision tag updated from v3.6.6 to v3.7.0. This indicates a new build of the page system, typically reflecting maintenance or minor fixes rather than changes to the study content.
    Difference
    0.1%
    Check dated 2026-09-16T00:06:59.000Z thumbnail image

Stay in the know with updates to T-VEC + Pembrolizumab in Sarcoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the T-VEC + Pembrolizumab in Sarcoma Clinical Trial page.